Editorial: Enhancing innate immunity in combination therapy for solid tumors

被引：0

作者：

Pejoski, David ^{[1
,2
,3
]}

机构：

[1] Adoram Therapeut, Geneva, Switzerland

[2] Univ Geneva, Sch Pharmaceut Sci, Geneva, Switzerland

[3] Univ Geneva, Inst Pharmaceut Sci Western Switzerland, Geneva, Switzerland

来源：

FRONTIERS IN IMMUNOLOGY | 2025年 / 15卷

关键词：

innate immunity; combination therapy; immuno-oncology; solid tumor; immunotherapy; cancer;

D O I：

10.3389/fimmu.2024.1539027

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页数：3

共 13 条

[1] Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations [J].

Butterfield, Lisa H. ;

Najjar, Yana G. .

NATURE REVIEWS IMMUNOLOGY, 2024, 24 (06) :399-416

[2] Editorial: New insights into innate immune cell-based immunotherapies in cancer [J].

Caignard, Anne ;

Poupot-Marsan, Mary ;

Lafont, Virginie ;

Wesch, Daniela ;

Porta, Chiara .

FRONTIERS IN IMMUNOLOGY, 2024, 15

[3] Tumour heterogeneity and resistance to cancer therapies [J].

Dagogo-Jack, Ibiayi ;

Shaw, Alice T. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (02) :81-94

[4] DNAM-1-chimeric receptor-engineered NK cells, combined with Nutlin-3a, more effectively fight neuroblastoma cells in vitro: a proof-of-concept study [J].

Focaccetti, Chiara ;

Benvenuto, Monica ;

Pighi, Chiara ;

Vitelli, Alessandra ;

Napolitano, Federico ;

Cotugno, Nicola ;

Fruci, Doriana ;

Palma, Paolo ;

Rossi, Paolo ;

Bei, Roberto ;

Cifaldi, Loredana .

FRONTIERS IN IMMUNOLOGY, 2022, 13

[5] Harnessing innate immune pathways for therapeutic advancement in cancer [J].

Hu, Ankang ;

Sun, Li ;

Lin, Hao ;

Liao, Yuheng ;

Yang, Hui ;

Mao, Ying .

SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)

[6] Advances in early detection methods for solid tumors [J].

Jiang, Bowen ;

Xie, Deqian ;

Wang, Shijin ;

Li, Xiunan ;

Wu, Guangzhen .

FRONTIERS IN GENETICS, 2023, 14

[7]

Lu Ligong, 2022, Curr Res Immunol, V3, P118, DOI 10.1016/j.crimmu.2022.05.003

[8] Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer [J].

Qin, Angel ;

Coffey, David G. ;

Warren, Edus H. ;

Ramnath, Nithya .

CANCER MEDICINE, 2016, 5 (09) :2567-2578

[9] Rational combination of cancer therapies with PD1 axis blockade [J].

Thommen, Daniela S. ;

Peeper, Daniel S. .

NATURE REVIEWS CANCER, 2024,

[10] Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape [J].

Upadhaya, Samik ;

Neftelinov, Svetoslav T. ;

Hodge, Jeffrey ;

Campbell, Jay .

NATURE REVIEWS DRUG DISCOVERY, 2022, 21 (07) :482-483

← 1 2 →